The global healthcare industry is experiencing rapid transformation as the rising prevalence of type 2 diabetes, chronic kidney disease (CKD), and cardiovascular disorders drives demand for advanced glucose-lowering therapies. According to Future Market Insights (FMI), the Dapagliflozin Market is projected to surge from USD 267.96 million in 2026 to USD 4,584.38 million by 2036, registering an...
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek